Quaker Bioventures News
Most Popular Quaker Bioventures Story
TetraLogic nabs $32M round for lead cancer therapy
Malvern, PA-based TetraLogic Pharmaceuticals has rounded up $32 million in Series C cash to back the development of its lead cancer drug, the early-stage TL32711. Clarus Ventures led the round with Read more...
Latest Headlines
- August 10, 2010
- August 25, 2009
- March 31, 2008
- November 1, 2007
- August 15, 2007
- August 2, 2007
- September 12, 2006
- August 9, 2006
- July 31, 2006
- June 28, 2006
- June 26, 2006
- April 19, 2006
- April 10, 2006
- February 22, 2006
- February 20, 2006
- September 29, 2005
- September 7, 2005
- July 13, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
